Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.28 (
chloramphenicol acetyltransferase
)
5,100
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The t(9;22) Philadelphia chromosome translocation fuses 5' regulatory and coding sequences of the BCR gene to the c-ABL proto-oncogene. This results in the formation of hybrid
BCR
-ABL mRNAs and proteins. The shift in ABL transcriptional control to the
BCR
promoter may play a role in cellular transformation mediated by this rearrangement. We have functionally localized the
BCR
promoter to a region 1 kb 5' of
BCR
exon 1 coding sequences by using a
chloramphenicol acetyltransferase
reporter gene assay. Nucleotide sequence analysis of this region revealed many consensus binding sequences for transcription factor SP1 as well as two potential CCAAT box binding factor sites and one putative helix-loop-helix transcription factor binding site. No TATA-like or "initiator" element sequences were found. Because of low steady-state levels of
BCR
mRNA and the high GC content (78%) of the promoter region, definitive mapping of transcription start sites required artificial amplification of
BCR
promoter-directed transcripts. Overexpression from the
BCR
promoter in a COS cell system was effective in demonstrating multiple transcription initiation sites. In order to assess the effects of chromosomal translocation on the transcriptional control of the BCR gene, we determined S1 nuclease protection patterns of poly(A)+ RNA from tumor cell lines. No differences were observed in the locations and levels of
BCR
transcription initiation sites between those lines that harbored the t(9;22) translocation and those that did not. This demonstrates that
BCR
promoter function remains intact in spite of genomic rearrangement. The
BCR
promoter is structurally similar to the ABL promoters. Together, this suggests that the structural fusion of
BCR
-ABL and not its transcriptional deregulation is primarily responsible for the transforming effect of the t(9;22) translocation.
...
PMID:Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. 190 Sep 18